Condition
Non-small Cell Lung Cancer Stage ⅢA
Total Trials
5
Recruiting
0
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
P 2 (4)
Trial Status
Unknown2
Active Not Recruiting1
Not Yet Recruiting1
Withdrawn1
Clinical Trials (5)
Showing 5 of 5 trials
NCT04699721Phase 2Active Not Recruiting
Clinical Study of Neoadjuvant Chemotherapy and Immunotherapy Combined With Probiotics in Patients With Resectable NSCLC
NCT06394427Not Yet RecruitingPrimary
Neoadjuvant Chemoimmunotherapy in Stage IIIA- N2IIIB Non-small Cell Lung Cancer
NCT04040361Phase 2Unknown
Neoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer (EAST ENERGY)
NCT03628144Phase 2Withdrawn
Immunonutrition to Reduce Toxicities in Non-Small Cell Lung Cancer
NCT02223611Phase 2Unknown
Clinical Observation of S1 Capsule for Stage Ⅱ-ⅢA Non-small Cell Lung Cancer After Complete Resection
Showing all 5 trials